Top-Foren

Forum Stunde Tag
Gesamt 102 3373
Börse 53 1644
Talk 21 980
Hot-Stocks 28 749
DAX 9 346

TEVA -- Zukunft mit Generika

Seite 1 von 5
neuester Beitrag: 22.03.17 22:48
eröffnet am: 27.08.08 18:01 von: 14051948Ki. Anzahl Beiträge: 122
neuester Beitrag: 22.03.17 22:48 von: alpenland Leser gesamt: 34079
davon Heute: 59
bewertet mit 6 Sternen

Seite: Zurück 1 | 2 | 3 | 4 | 5 | 5  Weiter  

29411 Postings, 3680 Tage 14051948KibbuzimTEVA -- Zukunft mit Generika

 
  
    #1
6
27.08.08 18:01

Über das israelische Pharmaunternehmen TEVA muß man nicht viel sagen,der auf Generika spezialisierte Pharmakonzern gehört zu den bekanntesten Unternehmen Israels.

 

Neue Studienergebnisse zu Parkinson Medikament

ADAGIO Trial Results Show Teva´s AZILECT(R) 1 mg Tablets Slow Progression of Parkinson´s Disease

Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA  videos nachrichten) announces that results of the phase III ADAGIO trial were presented today during the 12th Congress of European Federation of Neurological Societies (EFNS) in Madrid, Spain as part of a "Late Breaking News" session.

The ADAGIO study showed that Parkinson´s disease (PD) patients who took AZILECT(R) (rasagiline) 1mg tablets once-daily upon entry into the trial, demonstrated a significant improvement compared to those who initiated the drug 9 months later.

The 1mg dose met all three primary endpoints, as well as the secondary endpoint, with statistical significance.  The primary analysis included three hierarchical endpoints based on Total-UPDRS (Unified Parkinson´s Disease Rating Scale) scores:

A) superiority of slopes in weeks 12-36 (-0.05; p=0.013, 95%CI -0.08,-0.01),

B) change from baseline to week 72 (-1.7 units; p=0.025, 95%CI -3.15,-0.21), and

C) non-inferiority of slopes (0.15 margin) in weeks 48-72 (0.0; 90%CI -0.04,0.04).

The safety profile of AZILECT(R) seen in the ADAGIO study was similar to previous experience with AZILECT(R).

Main results were presented at the congress by Professor Olivier Rascol, M.D., Ph.D., Department of Clinical Pharmacology, University Hospital, Toulouse, France, one of two principal investigators of the trial.

"The rigorous trial design and the fact that all three primary endpoints were met with statistical significance reinforce the quality of the data, supporting the potential for AZILECT(R) to have an effect on disease progression," said Prof. Rascol.

"The successful outcome of the study provides further rationale for the early use of AZILECT(R) among Parkinson´s disease patients," he added. "Delaying disease progression is the most important unmet need in the management of Parkinson´s disease," stated Prof. C. Warren Olanow, professor and chairman of the Department of Neurology at the Mount Sinai School of Medicine, New York, NY, and ADAGIO co-principal investigator.

"The ADAGIO study, the first of its kind, was prospectively designed to demonstrate if AZILECT(R) can slow down the progression of Parkinson´s disease. Results of the study show that early treatment with once-daily rasagiline 1mg tablets provided significant clinical benefits that were not obtained by those patients where initiation of AZILECT(R) therapy was delayed by nine months."

 The ADAGIO study, one of the largest conducted in PD, included 1,176 patients with very early Parkinson´s disease in 14 countries and 129 medical centers who were randomized to receive rasagiline 1 or 2 mg/day for 72 weeks (early start) or placebo for 36 weeks followed by rasagiline 1 or 2 mg/day for 36 weeks (delayed start).

Description of trial results can be found online (http://www.abstracts2view.com/ana) in the abstract submitted by Prof. Olanow and Prof. Rascol to the 133rd Annual Meeting of the American Neurological Association, Salt Lake City, UT, September 21-24, 2008.

Prof. Olanow will be presenting these results during the Works in Progress poster session on Tuesday, September 23, 2008. The abstract was also chosen to be presented orally by Prof. Olanow on Tuesday from 11:45am-noon.

Teva intends to submit these results to the regulatory authorities in the U.S. and Europe. Based on these results, Teva will work with the regulatory authorities to incorporate the results into the label for AZILECT(R).

For more information on AZILECT(R), please visit www.azilect.com.

About the Study  

ADAGIO is a randomized, multi-center, double-blind, placebo-controlled, parallel-group study prospectively examining rasagiline´s potential disease-modifying effects in 1,176 patients with early, untreated Parkinson´s disease.

Patients from 129 centers in 14 countries were randomized to early-start treatment (72 weeks rasagiline 1 or 2 mg once daily) or delayed-start treatment (36 weeks placebo followed by 36 weeks rasagiline 1 or 2 mg once daily (active treatment phase)).

The primary analyses of the trial were based on change in total UPDRS (Unified Parkinson´s Disease Rating Scale) and included slope superiority of rasagiline over placebo in the placebo-controlled phase, change from baseline to week 72, and non-inferiority of early-start vs. delayed-start slopes during weeks 48-72 of the active phase. UPDRS is the most commonly used rating scale to assess disease status.

About AZILECT (R)  

AZILECT(R) 1mg tablets (rasagiline tablets) are indicated for the treatment of the signs and symptoms of Parkinson´s disease both as initial therapy alone and to be added to levodopa later in the disease. AZILECT(R) 1mg tablets are currently available in 30 countries, including the US, Canada, Israel, Mexico, and most of the EU countries.

About Parkinson´s Disease

Parkinson´s disease is an age-related degenerative disorder of the brain.

Symptoms can include: tremor, stiffness, slowness of movement, and impaired balance. An estimated four million people worldwide suffer from the disease, which usually affects people over the age of 60.

About Teva  

Teva Pharmaceutical Industries Ltd., headquartered in Israel, is among the top 20 pharmaceutical companies in the world and is the world´s leading generic pharmaceutical company.

The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products.

Over 80 percent of Teva´s sales are in North America and Europe.

Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:  This release contains forward-looking statements. Such statements are based on management´s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause Teva´s future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements, including statements relating to the results of the ADAGIO phase III trial and the potential efficacy or future market or marketability of AZILECT(R).

Following further analysis, Teva´s interpretation of the results could differ materially depending on a number of factors, and we caution investors not to place undue reliance on the forward-looking statements contained in this press release as there can be no guarantee that the results from the phase III trial discussed in this press release will be confirmed upon full analysis of the results of the trial and additional information relating to the safety, efficacy or tolerability of AZILECT(R) may be discovered upon further analysis of data from the phase III trial.

Even if the results described in this release are confirmed upon full analysis of the ADAGIO study, we cannot guarantee that AZILECT(R) will be approved for marketing in a timely manner, if at all, by regulatory authorities in the EU or in the U.S. Additional risks relating to Teva and its business are discussed in Teva´s Annual Report on Form 20-F and its other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

-----------
"Ein Deutscher ist ein Mensch,der keine Lüge aussprechen kann, ohne sie selbst zu glauben"(Theodor W. Adorno)
Seite: Zurück 1 | 2 | 3 | 4 | 5 | 5  Weiter  
96 Postings ausgeblendet.

3746 Postings, 1908 Tage FD2012TEVA im Fokus

 
  
    #98
13.02.17 17:53
C.Rose: Der Bericht zum IV. Quartal hat wohl überzeugt, obschon die aktuellen Probleme bleiben. Gleichwohl, Glückwunsch zu Deinem Investment. Ich bleibe aber auch "dran"
und schaue mal, wie die US-Börse heute schließt. Die Marktteilnehmer, zu denen ja auch die Fonds gehören, müssen sich halt entscheiden, wie sie die künftige Entwicklung einschätzen, also nicht nur die Analysten, die hier ihr Süppchen kochen.

Nach meiner Meinung hängt hier viel von ab.

Dann zahlt der Kleinaktionär, wie FD2012 gerne mehr, wenn's dann gerechtfertigt ist.  

4334 Postings, 4800 Tage alpenlandstelle stetigen Anstieg fest

 
  
    #99
15.02.17 16:52
nach einem Rückschlag von ca 45% ist derzeit Erholung angesagt.
ohne tiefere Kenntnisse habe ich heute paar Kilos KOC gekauft.

Die Rendite liegt bei 3.76%
das Durchschnittsziel auf 41.06£ (Yahoo)
Erwartungen:
Mean Estimate 4.07 4.26 17.76 18.14

auch sonst scheint mir diverses zu laufen, gerne Statements eines Kenners der Firma :-)
 

4334 Postings, 4800 Tage alpenlandkurz zum 4.Q; Anstieg Gewinn um 30%

 
  
    #100
15.02.17 17:05
(RTTNews.com) - Teva Pharmaceutical Industries Limited ( TEVA ) revealed a profit for its fourth quarter that climbed compared to the same period last year. The company said its bottom line advanced to $1.48 billion, or $1.38 per share. This was up from $1.14 billion, or $1.28 per share, in last year's fourth quarter.

 

4334 Postings, 4800 Tage alpenlandkleiner Irrtum

 
  
    #101
15.02.17 20:30

das Durchschnittsziel auf 41.06(Yahoo)

 

4334 Postings, 4800 Tage alpenlandeinige wollen in den USA raus

 
  
    #102
16.02.17 19:10

ist auch kein Wunder nach dem heftigen Anstieg.
Ich denke, dem Weiteranstieg sollte danach nichts im Wege stehen.



Teva led trading today, but its recent recovery came to a halt, and it fell 0.81%. (in Israel).

 In den USA derzeit: (erst der Tagesschluss wird noch mehr sagen)

TEVA35.86-2.47%

 

3 Postings, 273 Tage WiedzminNach dem Rücksetzer heute Long.

 
  
    #103
17.02.17 01:59
Hab nun eine Erste Position aufgebaut, 3,8% Dividendenrendite sollte helfen dran zu bleiben. Ich traue dem Unternehmen Positive Überraschungen zu und es ist nach nahezu allen Kriterien massiv unterbewertet. Zunächst würde ich 45 Dollar anpeilen. Nun braucht es Geduld :)  

4334 Postings, 4800 Tage alpenlandder Verkaufsdruck in den USA hat etwas nachgelasse

 
  
    #104
17.02.17 22:47

heute wurde noch etwa 7 mio Aktien gehandelt ca 1/2 des normalen Durchschnittes.
Wahrscheinlich haben div (Hedge)Fonds den schnellen Gewinn realisiert.
Trotzdem gibt's auch die gute Sicht:  https://investorplace.com/2017/02/...eva-turning-around/#.WKdtTPnhD50

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Is Turning Around

It's been tough for TEVA stock, but this generic drug maker is primed for a comeback

 

4334 Postings, 4800 Tage alpenlandErholung in Israel

 
  
    #105
19.02.17 18:38

Date Closing Price (0.01 NIS) Change (%) Base Price Opening Price High Low Turnover (NIS)
19/02/2017§13,750 ¨¨¨¨¨¨¨¨¨¨¨¨¨¨¨¨¨¨2.69%¨¨¨¨¨¨¨¨¨¨¨¨¨¨¨¨13,390¨¨¨¨¨¨¨¨¨¨¨¨¨¨13,550¨¨¨¨¨¨¨13,800¨13,470 64,262,920

 

4334 Postings, 4800 Tage alpenlandGrossinvestoren haben zugekauft

 
  
    #106
1
20.02.17 09:57

Bald kommt die Wende nach oben !
Grossinvestoren kaufen
(Fidelity hat etwas verkauft).



The largest institutional investor in Teva is Fidelity, which held 6.2% of the company at the beginning of 2017. Fidelity actually sold 4.5 million shares in the fourth quarter of 2016, whereas Capital Research Global Investments, Barrow Hanley Mewhinney & Strauss, and The Bank of New York Mellon, the four largest shareholders after Fidelity, bought an aggregate 42 million shares. It appears that most of the institutions expect a positive return on the stock. 

 

284 Postings, 2182 Tage GURUFOCUSAlpenland

 
  
    #107
20.02.17 13:08
Das habe ich auch am WE gesehen.
 

284 Postings, 2182 Tage GURUFOCUSAlpenland ...

 
  
    #108
20.02.17 15:02
Ich hatte da noch eine andere Quelle... .   -
http://www.marketwatch.com/story/...-shares-in-4th-quarter-2017-02-14

M. Meinung - Keine Empfehlung.  

4334 Postings, 4800 Tage alpenlandBull Case für TEVA

 
  
    #109
1
21.02.17 15:30

The Cautious Bull Case for TEVA Stock
Lau is an optimist, and for good reason. For starters, the market price for TEVA stock is at levels not seen since late 2013. As a result of the massive fallout, the forward-price-earnings ratio for Teva Pharmaceutical is less than 8. That?s absurdly below the pharma industry?s median forward P/E ratio of 14.7.  (investorplace.com)

in USA Pre-market: 37.48 +2.28 (6.48%)  :-)

 

4334 Postings, 4800 Tage alpenlandheute Dividendenabgang

 
  
    #110
28.02.17 10:30

dies scheint keine Negativauswirkungen auf den Kurs zu haben (wurde wohl in den letzten Tagen vorweg genommen).

Teva Pharmaceutical goes ex-dividend tomorrow

Feb. 27, 2017 6:49 AM ET|About: Teva Pharmaceutical Industries Limited (TEVA)
Teva Pharmaceutical (NYSE:TEVA) had declared $0.34/share quarterly dividend, in line with previous.

Payable March 20; for shareholders of record March 2; ex-div Feb. 28.

 

4334 Postings, 4800 Tage alpenlandTeva lanciert neues Generikum in USA

 
  
    #111
01.03.17 22:49

Teva launches generic Pristiq in U.S.

Mar. 1, 2017 11:20 AM ET|About: Teva Pharmaceutical In... (TEVA)|By: Douglas W. House, SA News Editor
Teva Pharmaceutical Industries (TEVA +0.2%) launches its generic version of Pfizer's (PFE +1%) antidepressant Pristiq (desvenlafaxine) in the U.S.

According to IMS, Pristiq's American sales are ~$883M per year.


mal schauen, ob Trump was dagegen hat ?

 

4334 Postings, 4800 Tage alpenlandhab mal paar weitere KO C zugelegt

 
  
    #112
02.03.17 10:37

in der Pipeline scheint schon noch was bereit zu sein.



An application for a new drug by Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) has been accepted by the Food and Drug Administration. Teva?s drug that is used to treat tardive dyskinesia, SD-809, has also been given priority review. This will allow the drug to be evaluated at a faster rate.

 

4334 Postings, 4800 Tage alpenlandnoch einer kauft

 
  
    #113
02.03.17 11:06
Euro am Sonntag-Tipp: Ich kaufe jetzt: TEVA | Nachricht | finanzen.net
Rainer Laborenz von der azemos vermögensmanagement GmbH hält die Aktie von TEVA für kaufenswert und lobt deren niedriges KGV und die hohe Dividenden-Rendite. 02.03.2017
 

284 Postings, 2182 Tage GURUFOCUSAlpenland

 
  
    #114
02.03.17 11:28
...hab mal paar weitere KO C zugelegt...
Darf ich wissen welchen Schein?
Danke im Voraus.  

4334 Postings, 4800 Tage alpenlandjeder soll nach seinem Gusto wählen..

 
  
    #115
1
02.03.17 15:02
Bankster schauen zu !

Ich halte PR0C4H
Kurs nahe innerer Wert, aber leider rel. grosser Spread (sie Bangsters).

Kurs in Israel unverändert.

 

176 Postings, 2311 Tage Klausi MausiAbwärts

 
  
    #116
1
07.03.17 16:22
Hat jemand Infos zum Absturz auf das 52W-T?
Das hätte ich nicht erwartet - die Zahlen sind doch gar nicht so schlecht.  

9256 Postings, 6292 Tage LalapoFrage ?

 
  
    #117
09.03.17 15:34
Divrendite liegt ja mittl. um beachtliche 4 % .

Wie sieht es in Israel mit der Quellensteuer aus ..jemand Erfarung ?

Danke  

9256 Postings, 6292 Tage LalapoInteressant ...

 
  
    #118
10.03.17 08:47
denke einfach so kauft man keine 42 Mio Aktien ..die können ganz schön Power aufbauen ..:-)


Fidelity verkauft 4,5 Mio Aktien ....

CRG/Barrow/BONY kaufen 42 Mio Aktien ...


The largest institutional investor in Teva is Fidelity, which held 6.2% of the company at the beginning of 2017. Fidelity actually sold 4.5 million shares in the fourth quarter of 2016, whereas Capital Research Global Investments, Barrow Hanley Mewhinney & Strauss, and The Bank of New York Mellon, the four largest shareholders after Fidelity, bought an aggregate 42 million shares. :) It appears that most of the institutions expect a positive return on the stock.

 

4334 Postings, 4800 Tage alpenlandLancierung eines neuen Generikas in den USA

 
  
    #121
1
19.03.17 18:33

TEVA ANNOUNCES LAUNCH OF AUTHORIZED GENERIC OF MINASTRIN® 24 FE (NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL TABLETS AND FERROUS FUMARATE TABLETS)

... (automatisch gekürzt) ...

http://www.tevapharm.com/news/...lets_in_the_united_states_03_17.aspx
Moderation
Moderator: st
Zeitpunkt: 20.03.17 10:50
Aktion: Kürzung des Beitrages
Kommentar: Urheberrechtsverletzung, ggf. Link-Einfügen nutzen
Original-Link: http://www.tevapharm.com/news/...e_united_states_03_17.aspx

 

 

4334 Postings, 4800 Tage alpenlandwirklich bald die Wende

 
  
    #122
1
22.03.17 22:48

Teva Pharmaceuticals (TEVA) ist eines der 40 Unternehmen, die für angebliche Preisfestsetzung verklagt werden. Die Aktie, die in der Nähe eines 10-Jahres-Tiefes, wahrscheinlich in allen schlechten Nachrichten voraus.

 

Seite: Zurück 1 | 2 | 3 | 4 | 5 | 5  Weiter  
   Antwort einfügen - nach oben
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Goldpreis
Meistgesucht
Daimler AG710000
Deutsche Bank AG514000
AURELIUS Equity Opp. SE & Co. KGaAA0JK2A
CommerzbankCBK100
Volkswagen AG Vz. (VW AG)766403
EVOTEC AG566480
E.ON SEENAG99
Nordex AGA0D655
Apple Inc.865985
Allianz840400
Deutsche Telekom AG555750
Infineon Technologies AG623100
BASFBASF11
SAP SE716460
BayerBAY001